XML 31 R20.htm IDEA: XBRL DOCUMENT
v3.25.3

SHARE-BASED COMPENSATION (Tables) | 3 Months Ended
--- | ---
Oct. 31, 2025
Defined Benefit Plan Disclosure [Line Items] |
SUMMARY OF NUMBER OF OPTIONS GRANTED | SUMMARY OF NUMBER OF OPTIONS GRANTED
|  | Number of options |  |  | Weighted average exercise price |  |  | Weighted average remaining contractual term (in years) |  |  | Aggregate intrinsic value |
Balance as of July 31, 2025 |  |  | 13,251 |  |  | $ | 896.61 |  |  |  | 1.62 |  |  | $ | - |
Granted (i) |  |  | 37,700 |  |  |  | 12.50 |  |  |  | 4.75 |  |  |  | - |
Balance as of October 31, 2025 |  |  | 50,951 |  |  |  | 242.15 |  |  |  | 3.87 |  |  |  | - |
Exercisable as of October 31, 2025 |  |  | 17,964 |  |  | $ | 663.87 |  |  |  | 2.26 |  |  | $ | - |
| (i) | On August 1, 2025, the Company granted 37,700 stock options to employees and members of the scientific advisory board at an exercise price of $12.50 per share. All options vest quarterly over two years. The options expire on August 1, 2030. The grant-date fair value of the award was $218,784. The fair value of options granted during the three-month period ended October 31, 2025 was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected volatility of 116%, expected term of 5.0 years, risk-free interest rate of 3.98%, dividend yield of 0%, and a stock price of $7.50 on the grant date.
SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS | SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS
Exercise price |  |  | Options outstanding as of October 31, 2025 |  |  | Weighted average remaining contractual term (years) |  |  | Options exercisable as of October 31, 2025 |  |  | Weighted average remaining contractual term (years) |  |  | Expiry Date
$ | 12.50 |  |  |  | 37,700 |  |  |  | 4.75 |  |  |  | 4,713 |  |  |  | 4.75 |  |  | August 01, 2030
$ | 60.00 |  |  |  | 333 |  |  |  | 4.20 |  |  |  | 333 |  |  |  | 4.20 |  |  | January 16, 2030
$ | 904.50 |  |  |  | 2,663 |  |  |  | 2.64 |  |  |  | 2,663 |  |  |  | 2.64 |  |  | June 20, 2028
$ | 1,074.00 |  |  |  | 136 |  |  |  | 2.33 |  |  |  | 136 |  |  |  | 2.33 |  |  | February 27, 2028
$ | 907.97 |  |  |  | 1,195 |  |  |  | 1.76 |  |  |  | 1,195 |  |  |  | 1.76 |  |  | August 02, 2027
$ | 706.50 |  |  |  | 206 |  |  |  | 1.56 |  |  |  | 206 |  |  |  | 1.56 |  |  | May 20, 2027
$ | 1,126.50 |  |  |  | 1,000 |  |  |  | 1.29 |  |  |  | 1,000 |  |  |  | 1.29 |  |  | February 16, 2027
$ | 1,270.50 |  |  |  | 3,160 |  |  |  | 1.20 |  |  |  | 3,160 |  |  |  | 1.20 |  |  | January 13, 2027
$ | 1,074.83 |  |  |  | 81 |  |  |  | 1.00 |  |  |  | 81 |  |  |  | 1.00 |  |  | November 01, 2026
$ | 636.00 |  |  |  | 400 |  |  |  | 0.47 |  |  |  | 400 |  |  |  | 0.47 |  |  | April 19, 2026
$ | 636.00 |  |  |  | 4,077 |  |  |  | 0.41 |  |  |  | 4,077 |  |  |  | 0.41 |  |  | March 29, 2026
|  |  |  |  | 50,951 |  |  |  |  |  |  |  | 17,964 |  |  |  |  |  |  |
SCHEDULE OF RESTRICTED STOCK UNITS GRANTED | The following table summarizes the number of RSU’s granted to directors under the Omnibus Plan for three-month period ended October 31, 2025: SCHEDULE OF RESTRICTED STOCK UNITS GRANTED
|  | Number of |  |  |  |
|  | RSU’s |  |  | Aggregate |
|  | outstanding |  |  | intrinsic value |
Balance, July 31, 2025 |  |  | - |  |  | $ | - |
Granted (i) |  |  | 40,000 |  |  |  | 376,000 |
Balance, October 31, 2025 |  |  | 40,000 |  |  | $ | 440,000 |
| (i) | On September 24, 2025, the Company granted 40,000 RSUs to directors under the Omnibus Plan. These RSUs vest in full on the earlier of September 23, 2028 or the occurrence of a change of control, resignation, or dismissal without cause. The grant-date fair value of these RSUs was $376,000.
SCHEDULE OF PERFORMANCE SHARE UNITS GRANTED | The following table summarizes the number of PSU’s granted under the Omnibus Plan for three-month period ended October 31, 2025: SCHEDULE OF PERFORMANCE SHARE UNITS GRANTED
|  | Number of |  |  |  |
|  | PSU’s |  |  | Aggregate |
|  | outstanding |  |  | intrinsic value |
Balance, July 31, 2025 |  |  | - |  |  | $ | - |
Granted (i) |  |  | 165,935 |  |  |  | 1,434,513 |
Balance, October 31, 2025 |  |  | 165,935 |  |  | $ | 1,825,285 |
| (i) | On August 1, 2025, the Company granted 165,935 performance-based stock units (“PSUs”) to the Chief Executive Officer (“CEO”), Chief Financial Officer (“CFO”), Chief Medical Officer (“CMO”), and Chief Scientific Officer (“CSO”) under the Omnibus Plan. These PSUs contain performance conditions tied to the advancement of the Company’s Bria-IMT Phase 3 program, the Bria-OTS program, and certain corporate and governance objectives. The grant-date fair value of the PSUs awarded to these officers totaled $353,228. The PSUs awarded to the CMO and CSO include milestones related to the Bria-OTS program, with grant-date fair values of $70,643 each. The CFO’s PSUs relate to corporate and financial reporting objectives, with a grant-date fair value of $70,643. On September 24, 2025, the Company granted 100,000 PSUs to a director under the Omnibus Plan. These PSUs contain performance conditions related to the Company’s corporate, strategic, and governance objectives. The grant-date fair value of this award was $940,000, determined using the closing price of the Company’s common stock on the grant date. The fair value of all PSU awards was determined using the closing price of the Company’s common stock on the respective grant dates. In accordance with ASC 718, management evaluates the probability of achieving each performance condition at each reporting date. As of October 31, 2025, management has determined that achievement of the applicable performance conditions is probable. Compensation cost is recognized over the requisite service period on a graded vesting (tranche-by-tranche) basis. As of October 31, 2025, no PSUs were vested or issuable, as all awards remained subject to their performance conditions. See Note 9 for PSUs that vested subsequent to the balance sheet date.
SCHEDULE OF SHARE-BASED COMPENSATION EXPENSES | SCHEDULE OF SHARE-BASED COMPENSATION EXPENSES
|  | Three months ended October 31, |
|  | 2025 |  |  | 2024 |
Research and development expenses |  | $ | 83,431 |  |  |  | 32,718 |
General and administrative expenses |  |  | 211,255 |  |  |  | 234,253 |
Total share-based compensation |  | $ | 294,686 |  |  |  | 266,971 |
Bria Pro Therapeutics Corp [Member] |
Defined Benefit Plan Disclosure [Line Items] |
SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS | SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS
Exercise Price |  |  | Options outstanding as of October 31, 2025 |  |  | Options exercisable as of October 31, 2025 |  |  | Expiry Date
$ | 0.0933 |  |  |  | 440,000 |  |  |  | 440,000 |  |  | June 20, 2028
$ | 0.1108 |  |  |  | 21,000 |  |  |  | 21,000 |  |  | February 27, 2028
$ | 0.0984 |  |  |  | 180,100 |  |  |  | 180,100 |  |  | August 02, 2027
$ | 0.0729 |  |  |  | 31,000 |  |  |  | 31,000 |  |  | May 20, 2027
$ | 0.1162 |  |  |  | 150,000 |  |  |  | 150,000 |  |  | February 16, 2027
$ | 0.1310 |  |  |  | 524,700 |  |  |  | 524,700 |  |  | January 13, 2027
$ | 0.1165 |  |  |  | 12,600 |  |  |  | 12,600 |  |  | November 01, 2026
$ | 0.0888 |  |  |  | 100,000 |  |  |  | 100,000 |  |  | September 01, 2026
$ | 0.0656 |  |  |  | 60,000 |  |  |  | 60,000 |  |  | April 19, 2026
$ | 0.0656 |  |  |  | 612,000 |  |  |  | 612,000 |  |  | March 29, 2026
|  |  |  |  | 2,131,400 |  |  |  | 2,131,400 |  |  |

X
- Definition Schedule Of Share Based Compensation Expenses [TableTextBlock] + References No definition available. + Details
Name: | BCTX_ScheduleOfShareBasedCompensationExpensesTableTextBlock
Namespace Prefix: | BCTX_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (k) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (j)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (j)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (j)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (j)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (c)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (c)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-7 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (q) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (m) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 + Details
Name: | us-gaap_DefinedBenefitPlanDisclosureLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Subparagraph (c) -Paragraph 2 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=BCTX_BriaProTherapeuticsCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |